Table 6.

Logistic Regression Model With Odds Ratios (ORs) and 95% CI of Improvement Rate of Performance Status.

	Univariable			Multivariable
Variable	Crude OR	95% CI	P	Adjusted OR	95% CI	P
Gender
Female	[reference]
Male	1.2	0.9-1.6	.294
Age, years
⩽60	[reference]
>60	0.8	0.6-1.2	.291
Body mass index, kg/m2
<18.5	[reference]
18.5-24	0.8	0.5-1.2	.264
>24	1.3	0.8-2.1	.303
Tumor type
Gastric cancer	[reference]			[reference]
Lung cancer	3.1	2.1-4.6	<.001	3.7	2.3-5.9	<.001
Breast cancer	3.0	1.9-4.6	<.001	3.1	1.9-5.1	<.001
Colorectal cancer	1.4	0.7-2.6	.371	0.3	0.1-1.0	.060
Cardiac and esophageal cancer	2.7	1.4-5.1	.002	2.5	1.3-4.8	.007
Hepatobiliary cancer	2.2	0.7-7.3	.200	2.6	0.7-9.1	.135
Ovarian cancer	5.8	3.1-10.9	<.001	6.8	3.4-13.7	<.001
TNM stage
I-II	[reference]
III-IV	1.0	0.7-1.4	.848
Node metastasis
Negative	[reference]			[reference]
Positive	0.4	0.3-0.6	<.001	0.4	0.3-0.6	<.001
Distant metastasis
Negative	[reference]			[reference]
Positive	0.3	0.2-0.4	<.001	0.2	0.2-0.4	<.001
Prior chemotherapy
No	[reference]
Yes	0.9	0.7-1.3	.683
Prior radiotherapy
No	[reference]
Yes	2.2	0.9-5.8	.094
ECOG score
0-1	[reference]			[reference]
⩾2	0.4	0.1-1.0	.045	0.3	0.1-0.9	.024
Hypertension
No	[reference]
Yes	1.4	0.9-2.1	.121
Renal insufficiency
No	[reference]
Yes	1.1	0.3-3.5	.918
Hepatic insufficiency
No	[reference]			[reference]
Yes	0.2	0.1-0.5	<.001	0.5	0.2-1.0	.037
Diabetes
No	[reference]
Yes	0.9	0.4-1.9	.793
Chemotherapy regimen
Platinum and fluorouracil based	[reference]			[reference]
Platinum and pemetrexed based	2.3	1.3-4.0	.003	1.2	0.6-2.3	.589
Irinotecan and fluorouracil based	1.0	0.5-1.8	.928	1.3	0.7-2.5	.444
Platinum and taxane based	1.6	0.8-3.0	.161	1.7	0.9-3.4	.127
Cyclophosphamide and adriamycin based	1.9	1.1-3.4	.019	1.1	0.6-2.0	.870
Targeted therapy and others regimen	1.8	1.2-2.5	.002	1.2	0.8-1.8	.353
Other Chinese medicine
ShenqiFuzheng injection
No	[reference]
Yes	1.1	0.8-1.5	.477
Glycopeptide injection
No	[reference]
Yes	1.0	0.7-1.4	.965
Kushen injection
No	[reference]
Yes	1.0	0.7-1.5	.975
Shenmai injection
No	[reference]
Yes	1,0	0.6-1.8	.878
DiyuShengbai tablet
No	[reference]
Yes	1.8	1.0-3.5	.067
Chemotherapy cycles
1-3	[reference]			[reference]
>3	2.1	1.5-2.8	<.001	2.8	2.1-3.9	<.001
Aidi injection used
No	[reference]			[reference]
Yes	2.9	2.1-4.1	<.001	3.4	2.4-4.8	<.001

Abbreviation: ECOG, Eastern Cooperative Oncology Group.

^aBoldfaced P values are statistically significant.